domperidone has been researched along with metformin in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (28.57) | 29.6817 |
2010's | 4 (57.14) | 24.3611 |
2020's | 1 (14.29) | 2.80 |
Authors | Studies |
---|---|
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Kumei, S; Miyagishi, S; Nozu, R; Nozu, T; Okumura, T; Takakusaki, K | 1 |
Abbas, HAA; Abdel-Karim, SAM; El-Ganiny, AMA; El-Sayed, MA | 1 |
7 other study(ies) available for domperidone and metformin
Article | Year |
---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Metformin inhibits visceral allodynia and increased gut permeability induced by stress in rats.
Topics: AMP-Activated Protein Kinases; Animals; Colon; Disease Models, Animal; Domperidone; Dopamine Antagonists; Evans Blue; Hyperalgesia; Hypoglycemic Agents; Intestinal Mucosa; Irritable Bowel Syndrome; Lipopolysaccharides; Male; Metformin; Naloxone; Narcotic Antagonists; NG-Nitroarginine Methyl Ester; Nociception; Permeability; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rats; Rats, Sprague-Dawley; Stress, Physiological; Sulpiride | 2019 |
Promising FDA-approved drugs with efflux pump inhibitory activities against clinical isolates of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Diclofenac; Domperidone; Humans; Metformin; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Nitroglycerin; Staphylococcal Infections; Staphylococcus aureus | 2022 |